Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Annovis Bio ( (ANVS) ) just unveiled an announcement.
On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 study for the drug buntanetap in early Alzheimer’s disease, marking a significant step toward market approval. The study, which follows promising results from previous trials, is designed to assess both symptomatic and potential disease-modifying effects over an 18-month period and involves over 750 participants across the United States.
More about Annovis Bio
Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is a late-stage clinical drug platform company focused on pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
YTD Price Performance: -38.55%
Average Trading Volume: 411,788
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $44.7M
For an in-depth examination of ANVS stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue